WuXi XDC Cayman company profile

2268 · HKEX · HKD

Compare WuXi XDC Cayman
$59.70Change from previous close: −5.61%Absolute change: −$3.55

Close · November 20, 2026

Company profile

WuXi XDC Cayman has 3,628 employees and is headquartered in Wuxi, China.

Operating in China, North America, Europe and other international markets, WuXi XDC Cayman Inc. provides contract research, development and manufacturing services. Its work covers the discovery, development and production of drug substances and drug products built on antibody-drug conjugates, bioconjugates and monoclonal antibody intermediates, along with payload-linker components. The company also develops and markets anti-tumor drugs and offers international sales contracting services. It has a strategic collaboration with Earendil Labs and with Akari Therapeutics.

The company was founded in 2013, is headquartered in Wuxi, China, and employs 3,628 people. In the fiscal year ended December 2025, revenue reached CNY 5.9 billion, a 46.7% increase, and net profit was CNY 1.5 billion. It is a subsidiary of WuXi Biologics (Cayman) Inc.

Company facts

Industry
Diagnostics & Research
Headquarters
No. 11 Xinhui Ring Road, Wuxi
Employees
3,628
Chief executive
Jincai Li
Founded
2013
Fiscal year
January - December
Listing
2268 · HKEX
Currency
HKD
ISIN
KYG9808A1058

WuXi XDC Cayman and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
WuXi XDC Cayman2268Hong Kong SAR China$9.64B3,62828.1%46.6
Sonic HealthcareSHLAustralia$7.13B47,0009.3%17.6
WuXi AppTec603259China$63.99B33,83444.8%15.7
QiagenQIAGermany$10.23B5,40026.7%28.5
bioMérieuxBIMFrance$11.84B14,56216.0%23.4
ICON PublicICLRUnited States$13.99B40,2502.7%74.7

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare WuXi XDC Cayman with its competitors